<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04982874</url>
  </required_header>
  <id_info>
    <org_study_id>447/STD/PML/2019</org_study_id>
    <nct_id>NCT04982874</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Furosemide 40 mg Tablet in 24 Indonesian Healthy Volunteers</brief_title>
  <official_title>Bioequivalence Study of Furosemide in Indonesian Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PT. Kimia Farma (Persero) Tbk</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PT Pharma Metric Labs</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>PT. Kimia Farma (Persero) Tbk</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research was to investigate whether Furosemide 40 mg tablet manufactured&#xD;
      by PT. Kimia Farma Tbk was bioequivalent to its reference drug and Lasix® 40 mg Tablet&#xD;
      manufactured by PT. Aventis Pharma, Indonesia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Twenty four healty volunteers were given a single dose of Furosemide 40 mg Tablet or Lasix®&#xD;
      40 mg Tablet with 240 mL of water beneath fasting condition. Then the blood samples for&#xD;
      Furosemide were drawn and analyzed using UPLC. All subjects sample plasma were analyzed for&#xD;
      pharmacokinetic evaluation&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 13, 2019</start_date>
  <completion_date type="Actual">January 29, 2020</completion_date>
  <primary_completion_date type="Actual">January 17, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>randomized, single blind, single dose, 2-period, cross-over design with one week washout period between each treatment in 24 healthy volunteers beneath fasting condition</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Geometric Mean Ratio</measure>
    <time_frame>1 month</time_frame>
    <description>The ratio between test drug and reference drug</description>
  </primary_outcome>
  <primary_outcome>
    <measure>90% confidence intervals</measure>
    <time_frame>1 month</time_frame>
    <description>The two products are considered bioequivalent when the 90% confidence intervals of the furosemide geometric mean ratio between test and reference product fall within the range of 80.00-125.00% for AUCt and Cmax.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics parameter</measure>
    <time_frame>1 month</time_frame>
    <description>Maximum plasma concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics parameter</measure>
    <time_frame>1 month</time_frame>
    <description>Area Under Curve from 0 to 24 hours (AUCt)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Drug Use</condition>
  <arm_group>
    <arm_group_label>Furosemide 40 mg tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>volunteers received Furosemide 40 mg tablet with 240 mL of water</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lasix® 40 mg Tablet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>volunteers received Lasix® 40 mg tablet with 240 mL of water</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Furosemide 40 mg</intervention_name>
    <description>Administered with 240 mL of water</description>
    <arm_group_label>Furosemide 40 mg tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lasix® 40 mg Tablet</intervention_name>
    <description>Administered with 240 mL of water</description>
    <arm_group_label>Lasix® 40 mg Tablet</arm_group_label>
    <other_name>Furosemide 40 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  have read the subject information and signed informed consent documents&#xD;
&#xD;
          -  age 18 - 55 years&#xD;
&#xD;
          -  body mass index between 18-25 kg/m2&#xD;
&#xD;
          -  have a normal electrocardiogram&#xD;
&#xD;
          -  blood pressure within normal range (systolic 90-120 mmHg and diastolic 60-80 mmHg)&#xD;
&#xD;
          -  heart rate within normal range (60-100 bpm)&#xD;
&#xD;
          -  with absence of significant disease or clinically significant abnormal laboratory&#xD;
             values on laboratory evaluation, medical history or physical examination during&#xD;
             screening&#xD;
&#xD;
          -  acceptance to use protection (condom) during intercourse with their spouse throughout&#xD;
             the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  those who are pregnant and/or nursing women&#xD;
&#xD;
          -  those with a history of hypersensitivity to furosemide, or other diuretics or other&#xD;
             ingredients in the drugs or a history of serious allergic reaction to any drug, a&#xD;
             significant allergic disease, or allergic reaction&#xD;
&#xD;
          -  those with a history or presence of medical condition which might significantly&#xD;
             influence the pharmacokinetic of the study drug, e.g. chronic gastrointestinal&#xD;
             disease, diarrhea, gastric surgery, renal insufficiency, hepatic dysfunction or&#xD;
             cardiovascular disease.&#xD;
&#xD;
          -  those with a history or presence of any coagulation disorder or clinically significant&#xD;
             hematology abnormalities&#xD;
&#xD;
          -  those who are using any medication (prescription or non-prescription drug, food&#xD;
             supplement, herbal medicine), particularly the medication known to affect the&#xD;
             pharmacokinetic of the study drug, within one week prior to the drug administration&#xD;
             day&#xD;
&#xD;
          -  those who have participated in any clinical study within 3 months prior to the study&#xD;
             (&lt; 90 days)&#xD;
&#xD;
          -  those who have donated or lost 300 ml (or more) of blood within 3 months prior to the&#xD;
             study&#xD;
&#xD;
          -  those who smoke more than 10 cigarettes a day&#xD;
&#xD;
          -  those who are positive to HIV, HBsAg, and HCV tests (to be kept confidential)&#xD;
&#xD;
          -  those with a history of drug or alcohol abuse within 12 months prior to screening for&#xD;
             this study&#xD;
&#xD;
          -  those who are unlikely to comply with the protocol, e.g uncooperative attitude,&#xD;
             inability to return for follow up visits, poor venous access&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frans D Suyatna</last_name>
    <role>Principal Investigator</role>
    <affiliation>PT Pharma Metric Labs</affiliation>
  </overall_official>
  <overall_official>
    <last_name>I Gusti Putu Bagus Diana Virgo</last_name>
    <role>Study Director</role>
    <affiliation>PT Pharma Metric Labs</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PT Pharma Metric Labs</name>
      <address>
        <city>Jakarta Pusat</city>
        <state>DKI Jakarta</state>
        <zip>10520</zip>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <results_reference>
    <citation>Chow SC. Bioavailability and Bioequivalence in Drug Development. Wiley Interdiscip Rev Comput Stat. 2014;6(4):304-312.</citation>
    <PMID>25215170</PMID>
  </results_reference>
  <results_reference>
    <citation>Oh SW, Han SY. Loop Diuretics in Clinical Practice. Electrolyte Blood Press. 2015 Jun;13(1):17-21. doi: 10.5049/EBP.2015.13.1.17. Epub 2015 Jun 30. Review.</citation>
    <PMID>26240596</PMID>
  </results_reference>
  <results_reference>
    <citation>Najib N, Idkaidek N, Beshtawi M, Bader M, Admour I, Alam SM, Zaman Q, Dham R. Bioequivalence evaluation of two brands of furosemide 40 mg tablets (Salurin and Lasix) in healthy human volunteers. Biopharm Drug Dispos. 2003 Sep;24(6):245-9.</citation>
    <PMID>12973821</PMID>
  </results_reference>
  <results_reference>
    <citation>Shankar SS, Brater DC. Loop diuretics: from the Na-K-2Cl transporter to clinical use. Am J Physiol Renal Physiol. 2003 Jan;284(1):F11-21. Review.</citation>
    <PMID>12473535</PMID>
  </results_reference>
  <results_reference>
    <citation>Brater DC. Diuretic therapy. N Engl J Med. 1998 Aug 6;339(6):387-95. Review.</citation>
    <PMID>9691107</PMID>
  </results_reference>
  <results_reference>
    <citation>Sica DA. Diuretic use in renal disease. Nat Rev Nephrol. 2011 Dec 20;8(2):100-9. doi: 10.1038/nrneph.2011.175. Review.</citation>
    <PMID>22183505</PMID>
  </results_reference>
  <results_reference>
    <citation>Ponto LL, Schoenwald RD. Furosemide (frusemide). A pharmacokinetic/pharmacodynamic review (Part I). Clin Pharmacokinet. 1990 May;18(5):381-408. Review.</citation>
    <PMID>2185908</PMID>
  </results_reference>
  <results_reference>
    <citation>Midha KK, McKay G. Bioequivalence; its history, practice, and future. AAPS J. 2009 Dec;11(4):664-70. doi: 10.1208/s12248-009-9142-z. Epub 2009 Oct 6. Review.</citation>
    <PMID>19806461</PMID>
  </results_reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 18, 2021</study_first_submitted>
  <study_first_submitted_qc>July 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 29, 2021</study_first_posted>
  <last_update_submitted>August 4, 2021</last_update_submitted>
  <last_update_submitted_qc>August 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bioequivalence</keyword>
  <keyword>furosemide</keyword>
  <keyword>Indonesian healthy volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Furosemide</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>October 6, 2021</submitted>
    <returned>November 4, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

